There is a risk of patient harm arising through medication error during a transition period where the original and new formulation of Rybelsus ® tablets, with different stated mg dose but similar bioavailability, will both be available on the market.
Similar Posts
Health Institution Exemption – Stakeholder survey
The MHRA invites health institutions in Great Britain to share their experience of the health institution exemption (sometimes referred to as an in-house manufacturing exemption).
Device specific vigilance guidance: Artificial Heart Valves
Guidance for manufacturers of artificial heart valves. It outlines specific scenarios that should be considered when determining if an incident is reportable.
MHRA Safety Roundup: September 2025
Summary of the latest safety advice for medicines and medical device users
MHRA Safety Roundup: July 2025
Summary of the latest safety advice for medicines and medical device users
Guidance: Medical devices: Standardised format for the periodic safety update report
Information and recommendations for manufacturers on the preparation and presentation of a periodic safety update report (PSUR).
Class 4 Medicines Defect Notification: Levetiracetam Accord 100mg/ml oral solution, Accord Healthcare Limited, UK, EL(25)A/40
Accord Healthcare Limited, UK has informed the MHRA that the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC) do not contain all the required safety information.